ALKERMES | ALKS - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
ALKERMES USD 4.39B 135.05M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Coherus Biosciences USD 191.18M 74.84M 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
Heron Therapeutics USD 246.22M 9.66M 2026-03
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
J&J USD 201.06B 167M 2026-06
Malin Corporation EUR 198.5M 70.1M 2024-12
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Otsuka Holdings JPY 4.4T 186.7B 2026-06
Ovoca Bio EUR 2.07M 414K 2025-12
Pfizer USD 201.13B 6.49B 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06